Comparison of time to clinically meaningful improvement in quality of life in neurological disorders in patients treated with natalizumab versus ocrelizumab
Authors:
Open Access
- 2 January 2024
- journal article
- research article
- Published by Taylor & Francis in Neurodegenerative Disease Management
- Vol. 14 (2) , 21-33
Abstract
Aim: To assess time to improvement in Quality of Life in Neurological Disorders (Neuro-QoL) domains for patients treated with natalizumab versus ocrelizumab. Methods: Patients enrolled in the MS PA... Plain language summary Knowledge of treatment-related benefits associated with medication choices, including improvement of quality of life (QoL), are strong influential factors for patients to sta... Tweetable abstract Natalizumab had shorter time to clinically meaningful improvement in the Neuro-QoL domains, Cognitive Function, Sleep Disturbance, Social Role Participation and Social Role Satis...Keywords
Funding Information
- Biogen
This publication has 23 references indexed in Scilit:
- Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label StudyCNS Drugs, 2022
- Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label StudyAdvances in Therapy, 2021
- Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort studyThe Lancet Neurology, 2020
- Adherence to treatment and related factors among patients with chronic conditions in primary care: a cross-sectional studyBMC Family Practice, 2019
- Review: Patient-reported outcomes in multiple sclerosis careMultiple Sclerosis and Related Disorders, 2019
- Medication adherence among patients with chronic diseases: a survey-based study in pharmaciesQJM: An International Journal of Medicine, 2019
- Rheumatoid Arthritis Patients’ Motivations for Accepting or Resisting Disease‐Modifying Antirheumatic Drug Treatment RegimensArthritis Care & Research, 2018
- Barriers and facilitators to medication adherence: a qualitative study with general practitionersBMJ Open, 2018
- Validating Neuro-QoL short forms and targeted scales with people who have multiple sclerosisMultiple Sclerosis Journal, 2015
- Clinical effects of natalizumab on multiple sclerosis appear early in treatment courseJournal of Neurology, 2013